M Victoria Cachofeiro

List of Publications by Year in Descending Order

115 papers	3,777 citations	32 h-index	56 g-index
125 ext. papers	4,270 ext. citations	4.9 avg, IF	4.76 L-index

#	Paper	IF	Citations
115	Oxidative Stress and Vascular Damage in the Context of Obesity: The Hidden Guest. *Antioxidants*, **2021**, 10,	7.1	3
114	Role of endoplasmic reticulum stress in renal damage after myocardial infarction. *Clinical Science*, **2021**, 135, 143-159	6.5	2
113	Fibrosis, the Bad Actor in Cardiorenal Syndromes: Mechanisms Involved. *Cells*, **2021**, 10,	7.9	1
112	The Interplay of Mitochondrial Oxidative Stress and Endoplasmic Reticulum Stress in Cardiovascular Fibrosis in Obese Rats. *Antioxidants*, **2021**, 10,	7.1	3
111	Secreted Phospholipase A-IIA Modulates Transdifferentiation of Cardiac Fibroblast through EGFR Transactivation: An Inflammation-Fibrosis Link. *Cells*, **2020**, 9,	7.9	7
110	The Crosstalk between Cardiac Lipotoxicity and Mitochondrial Oxidative Stress in the Cardiac Alterations in Diet-Induced Obesity in Rats. *Cells*, **2020**, 9,	7.9	14
109	The Interaction between Mitochondrial Oxidative Stress and Gut Microbiota in the Cardiometabolic Consequences in Diet-Induced Obese Rats. *Antioxidants*, **2020**, 9,	7.1	11
108	Identification of a Plasma Microrna Signature as Biomarker of Subaneurysmal Aortic Dilation in Patients with High Cardiovascular Risk. *Journal of Clinical Medicine*, **2020**, 9,	5.1	1
107	The Impact of Cardiac Lipotoxicity on Cardiac Function and Mirnas Signature in Obese and Non-Obese Rats with Myocardial Infarction. *Scientific Reports*, **2019**, 9, 444	4.9	10
106	The role of mitochondrial oxidative stress in the metabolic alterations in diet-induced obesity in rats. *FASEB Journal*, **2019**, 33, 12060-12072	0.9	19
105	Emerging Roles of Lysyl Oxidases in the Cardiovascular System: New Concepts and Therapeutic Challenges. *Biomolecules*, **2019**, 9,	5.9	16
104	Galectin-3 down-regulates antioxidant peroxiredoxin-4 in human cardiac fibroblasts: a new pathway to induce cardiac damage. *Clinical Science*, **2018**, 132, 1471-1485	6.5	26
103	Inhibition of galectin-3 ameliorates the consequences of cardiac lipotoxicity in a rat model of diet-induced obesity. *DMM Disease Models and Mechanisms*, **2018**, 11,	4.1	22
102	Aldosterone Impairs Mitochondrial Function in Human Cardiac Fibroblasts via A-Kinase Anchor Protein 12. *Scientific Reports*, **2018**, 8, 6801	4.9	19
101	The impact of obesity in the cardiac lipidome and its consequences in the cardiac damage observed in obese rats. *Clínica E Investigación En Arteriosclerosis (English Edition)*, **2018**, 30, 10-20	0.3	
100	A role for fumarate hydratase in mediating oxidative effects of galectin-3 in human cardiac fibroblasts. *International Journal of Cardiology*, **2018**, 258, 217-223	3.2	13
99	Galectin-3 pharmacological inhibition attenuates early renal damage in spontaneously hypertensive rats. *Journal of Hypertension*, **2018**, 36, 368-376	1.9	25

98	The impact of obesity in the cardiac lipidome and its consequences in the cardiac damage observed in obese rats. *Clínica E Investigación En Arteriosclerosis*, **2018**, 30, 10-20	1.4	1
97	mPGES-1 (Microsomal Prostaglandin E Synthase-1) Mediates Vascular Dysfunction in Hypertension Through Oxidative Stress. *Hypertension*, **2018**, 72, 492-502	8.5	19
96	High levels of circulating TNFR1 increase the risk of all-cause mortality and progression of renal disease in type 2 diabetic nephropathy. *Nephrology*, **2017**, 22, 354-360	2.2	11
95	A role for galectin-3 in the development of early molecular alterations in short-term aortic stenosis. *Clinical Science*, **2017**, 131, 935-949	6.5	14
94	The role of oxidative stress in the crosstalk between leptin and mineralocorticoid receptor in the cardiac fibrosis associated with obesity. *Scientific Reports*, **2017**, 7, 16802	4.9	22
93	The lysyl oxidase inhibitor (β-aminopropionitrile) reduces leptin profibrotic effects and ameliorates cardiovascular remodeling in diet-induced obesity in rats. *Journal of Molecular and Cellular Cardiology*, **2016**, 92, 96-104	5.8	39
92	Galectin-3 Blockade Reduces Renal Fibrosis in Two Normotensive Experimental Models of Renal Damage. *PLoS ONE*, **2016**, 11, e0166272	3.7	34
91	Role for Galectin-3 in Calcific Aortic Valve Stenosis. *Journal of the American Heart Association*, **2016**, 5,	6	40
90	Obesity-induced cardiac lipid accumulation in adult mice is modulated by G protein-coupled receptor kinase 2 levels. *Cardiovascular Diabetology*, **2016**, 15, 155	8.7	32
89	Galectin-3 blockade inhibits cardiac inflammation and fibrosis in experimental hyperaldosteronism and hypertension. *Hypertension*, **2015**, 66, 767-75	8.5	99
88	Interleukin-33/ST2 system attenuates aldosterone-induced adipogenesis and inflammation. *Molecular and Cellular Endocrinology*, **2015**, 411, 20-7	4.4	18
87	Galectin-3 Participates in Cardiovascular Remodeling Associated With Obesity. *Hypertension*, **2015**, 66, 961-9	8.5	54
86	The lysyl oxidase inhibitor β-aminopropionitrile reduces body weight gain and improves the metabolic profile in diet-induced obesity in rats. *DMM Disease Models and Mechanisms*, **2015**, 8, 543-51	4.1	25
85	The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries. *JACC: Heart Failure*, **2015**, 3, 59-67	7.9	127
84	Antagonistic effect of TNF-alpha and insulin on uncoupling protein 2 (UCP-2) expression and vascular damage. *Cardiovascular Diabetology*, **2014**, 13, 108	8.7	12
83	Leptin induces cardiac fibrosis through galectin-3, mTOR and oxidative stress: potential role in obesity. *Journal of Hypertension*, **2014**, 32, 1104-14; discussion 1114	1.9	85
82	Galectin-3 mediates aldosterone-induced vascular fibrosis. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2013**, 33, 67-75	9.4	255
81	Mercury induces proliferation and reduces cell size in vascular smooth muscle cells through MAPK, oxidative stress and cyclooxygenase-2 pathways. *Toxicology and Applied Pharmacology*, **2013**, 268, 188-200	4.6	43

80	Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial. *American Journal of Kidney Diseases*, **2013**, 61, 211-8	7.4	55
79	Aerobic exercise reduces oxidative stress and improves vascular changes of small mesenteric and coronary arteries in hypertension. *British Journal of Pharmacology*, **2013**, 168, 686-703	8.6	93
78	Left and right ventricle late remodeling following myocardial infarction in rats. *PLoS ONE*, **2013**, 8, e64986	3.7	47
77	A role for soluble ST2 in vascular remodeling associated with obesity in rats. *PLoS ONE*, **2013**, 8, e79176	3.7	29
76	A wound-like inflammatory aortic response in chronic portal hypertensive rats. *Molecular Immunology*, **2012**, 51, 177-87	4.3	7
75	Papel de la quinasa regulada por suero y glucocorticoides 1 en las alteraciones cardiacas producidas por la aldosterona en ratas. *Clínica E Investigación En Arteriosclerosis*, **2012**, 24, 267-274	1.4	
74	Anatomical and functional alterations of the heart in morbid obesity. Changes after bariatric surgery. *Revista Espanola De Cardiologia*, **2012**, 65, 14-21	1.5	45
73	Papel de la angiotensina II en el proceso aterosclerótico. *Clínica E Investigación En Arteriosclerosis*, **2012**, 24, 92-101	1.4	
72	Hipertensión portal: desarrollo de una respuesta inflamatoria sistémica asociada a síndrome metabólico. *Clínica E Investigación En Arteriosclerosis*, **2012**, 24, 157-166	1.4	
71	Spironolactone prevents alterations associated with cardiac hypertrophy produced by isoproterenol in rats: involvement of serum- and glucocorticoid-regulated kinase type 1. *Experimental Physiology*, **2012**, 97, 710-8	2.4	11
70	Ezetimibe inhibits PMA-induced monocyte/macrophage differentiation by altering microRNA expression: a novel anti-atherosclerotic mechanism. *Pharmacological Research*, **2012**, 66, 536-43	10.2	23
69	Brown fat lipoatrophy and increased visceral adiposity through a concerted adipocytokines overexpression induces vascular insulin resistance and dysfunction. *Endocrinology*, **2012**, 153, 1242-55	4.8	24
68	The effects of adiponectin and leptin on human endothelial cell proliferation: a live-cell study. *Journal of Vascular Research*, **2012**, 49, 111-22	1.9	10
67	Cardiotrophin-1 induces sarcoplasmic reticulum Ca(2+) leak and arrhythmogenesis in adult rat ventricular myocytes. *Cardiovascular Research*, **2012**, 96, 81-9	9.9	19
66	The impact of bariatric surgery on renal and cardiac functions in morbidly obese patients. *Nephrology Dialysis Transplantation*, **2012**, 27 Suppl 4, iv53-7	4.3	17
65	DIOL triterpenes block profibrotic effects of angiotensin II and protect from cardiac hypertrophy. *PLoS ONE*, **2012**, 7, e41545	3.7	19
64	Efecto del tratamiento con candesartan sobre los mecanismos y factores implicados en el desarrollo de la enfermedad cardiovascular asociada a sobrepeso y exceso de tejido adiposo visceral en la rata. *Clínica E Investigación En Arteriosclerosis*, **2011**, 23, 55-61	1.4	
63	Structural, functional, and molecular alterations produced by aldosterone plus salt in rat heart: association with enhanced serum and glucocorticoid-regulated kinase-1 expression. *Journal of Cardiovascular Pharmacology*, **2011**, 57, 114-21	3.1	17

62	Cardiac benefits of exercise training in aging spontaneously hypertensive rats. *Journal of Hypertension*, **2011**, 29, 2349-58	1.9	32
61	Rosuvastatin restored adrenergic and nitrergic function in mesenteric arteries from obese rats. *British Journal of Pharmacology*, **2011**, 162, 271-85	8.6	26
60	Endothelial dysfunction of rat coronary arteries after exposure to low concentrations of mercury is dependent on reactive oxygen species. *British Journal of Pharmacology*, **2011**, 162, 1819-31	8.6	59
59	Exposure to low mercury concentration in vivo impairs myocardial contractile function. *Toxicology and Applied Pharmacology*, **2011**, 255, 193-9	4.6	21
58	Interplay of hypertension, inflammation, and angiotensin II. *American Journal of Hypertension*, **2011**, 24, 1059	2.3	8
57	A role for cardiotrophin-1 in myocardial remodeling induced by aldosterone. *American Journal of Physiology - Heart and Circulatory Physiology*, **2011**, 301, H2372-82	5.2	48
56	A proteomic approach to determine changes in proteins involved in the myocardial metabolism in left ventricles of spontaneously hypertensive rats. *Cellular Physiology and Biochemistry*, **2010**, 25, 347-58	3.9	18
55	Aldosterone and the cardiovascular system: a dangerous association. *Hormone Molecular Biology and Clinical Investigation*, **2010**, 4, 539-48	1.3	2
54	Mechanisms underlying the activation of L-type calcium channels by urocortin in rat ventricular myocytes. *Cardiovascular Research*, **2010**, 87, 459-66	9.9	27
53	The presence of abdominal obesity is associated with changes in vascular function independently of other cardiovascular risk factors. *International Journal of Cardiology*, **2010**, 139, 32-41	3.2	36
52	Papel de las estatinas en la enfermedad renal crónica (ERC). *Clínica E Investigación En Arteriosclerosis*, **2010**, 22, 17-24	1.4	
51	Response to STreatment with statins may be considered in ESRD patients for primary prevention of cardiovascular diseaseS *Kidney International*, **2009**, 75, 1355	9.9	
50	Inflammation: A Link Between Hypertension and Atherosclerosis. *Current Hypertension Reviews*, **2009**, 5, 40-48	2.3	16
49	Urocortin induces positive inotropic effect in rat heart. *Cardiovascular Research*, **2009**, 83, 717-25	9.9	27
48	Inflammation but not endothelial dysfunction is associated with the severity of coronary artery disease in dyslipidemic subjects. *Mediators of Inflammation*, **2009**, 2009, 469169	4.3	19
47	Cardiac L-type calcium current is increased in a model of hyperaldosteronism in the rat. *Experimental Physiology*, **2009**, 94, 675-83	2.4	16
46	The protective effect of irbesartan in rats fed a high fat diet is associated with modification of leptin-adiponectin imbalance. *Journal of Hypertension*, **2009**, 27, S37-41	1.9	20
45	Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study. *Clinical Therapeutics*, **2008**, 30, 84-97	3.5	15

44	Aldosterone and the vascular system. *Journal of Steroid Biochemistry and Molecular Biology*, **2008**, 109, 331-5	5.1	63
43	Participaci□ de los mineralocorticoides en la respuesta inflamatoria vascular asociada a la hipertensi□. *C□nica E Investigaci□n En Arteriosclerosis*, **2008**, 20, 233-238	1.4	
42	Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease. *Kidney International*, **2008**, S4-9	9.9	379
41	Specific amelioration of cerebral endothelial dysfunction in hypertensive patients treated with atorvastatin. *American Journal of Hypertension*, **2008**, 21, 604	2.3	1
40	Effects of isoproterenol treatment for 7 days on inflammatory mediators in the rat aorta. *American Journal of Physiology - Heart and Circulatory Physiology*, **2008**, 295, H211-9	5.2	43
39	Fenofibrate and pioglitazone do not ameliorate the altered vascular reactivity in aorta of isoproterenol-treated rats. *Journal of Cardiovascular Pharmacology*, **2008**, 52, 413-21	3.1	5
38	Endothelial dysfunction, oxidative stress and inflammation in atherosclerosis: beneficial effects of statins. *Current Medicinal Chemistry*, **2007**, 14, 243-8	4.3	120
37	Interactions between aldosterone and connective tissue growth factor in vascular and renal damage in spontaneously hypertensive rats. *Journal of Hypertension*, **2007**, 25, 629-38	1.9	27
36	Efecto de la atorvastatina sobre la expresi□ vascular de los PPAR en conejos dislip□micos. *C□nica E Investigaci□n En Arteriosclerosis*, **2007**, 19, 166-173	1.4	0
35	Papel del factor de crecimiento de tejido conectivo en el da□ vascular asociado a hipertensi□ en ratas. Interacci□ con la aldosterona. *C□nica E Investigaci□n En Arteriosclerosis*, **2007**, 19, 232-239	1.4	
34	Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease. *Journal of the American Society of Nephrology: JASN*, **2006**, 17, S231-5	12.7	67
33	Role of connective tissue growth factor in vascular and renal damage associated with hypertension in rats. Interactions with angiotensin II. *JRAAS - Journal of the Renin-Angiotensin-Aldosterone System* , **2006**, 7, 192-200	3	26
32	Oxidative stress in uremia: the role of anemia correction. *Journal of the American Society of Nephrology: JASN*, **2006**, 17, S174-7	12.7	30
31	Insulin resistance, inflammatory biomarkers, and adipokines in patients with chronic kidney disease: effects of angiotensin II blockade. *Journal of the American Society of Nephrology: JASN*, **2006**, 17, S206-12	12.7	84
30	Participation of aldosterone in the vascular inflammatory response of spontaneously hypertensive rats: role of the NFkappaB/IkappaB system. *Journal of Hypertension*, **2005**, 23, 1167-72	1.9	46
29	AT-1 receptor antagonism modifies the mediation of endothelin-1, thromboxane A2, and catecholamines in the renal constrictor response to angiotensin II. *Kidney International*, **2005**, S3-9	9.9	11
28	Effect of recombinant human growth hormone administration on body composition and vascular function and structure in old male Wistar rats. *Biogerontology*, **2005**, 6, 303-12	4.5	21
27	Effect of AT1 receptor antagonism on vascular and circulating inflammatory mediators in SHR: role of NF-kappaB/IkappaB system. *American Journal of Physiology - Heart and Circulatory Physiology*, **2005**, 288, H111-5	5.2	102

26	Participation of prostacyclin in endothelial dysfunction induced by aldosterone in normotensive and hypertensive rats. *Hypertension*, **2005**, 46, 107-12	8.5	98
25	Eplerenone reduces oxidative stress and enhances eNOS in SHR: vascular functional and structural consequences. *Antioxidants and Redox Signaling*, **2005**, 7, 1294-301	8.4	60
24	Aldosterone modulates neural vasomotor response in hypertension: role of calcitonin gene-related peptide. *Regulatory Peptides*, **2004**, 120, 253-60		24
23	Chronic l-arginine treatment reduces vascular smooth muscle cell hypertrophy through cell cycle modifications in spontaneously hypertensive rats. *Journal of Hypertension*, **2004**, 22, 751-8	1.9	10
22	Comparison between the effects of mixed dyslipidaemia and hypercholesterolaemia on endothelial function, atherosclerotic lesions and fibrinolysis in rabbits. *Clinical Science*, **2003**, 104, 357-365	6.5	9
21	Comparison between the effects of mixed dyslipidaemia and hypercholesterolaemia on endothelial function, atherosclerotic lesions and fibrinolysis in rabbits. *Clinical Science*, **2003**, 104, 357-65	6.5	10
20	Synergistic effect of angiotensin-converting enzyme (ACE) and 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibition on inflammatory markers in atherosclerotic rabbits. *Clinical Science*, **2003**, 105, 655-62	6.5	21
19	Effect of AT1 receptor blockade on hepatic redox status in SHR: possible relevance for endothelial function?. *American Journal of Physiology - Regulatory Integrative and Comparative Physiology*, **2003**, 285, R674-81	3.2	32
18	Role of endothelin-1 and thromboxane A2 in renal vasoconstriction induced by angiotensin II in diabetes and hypertension. *Kidney International*, **2002**, S2-7	9.9	17
17	Renal dysfunction after chronic blockade of nitric oxide synthesis. *Antioxidants and Redox Signaling*, **2002**, 4, 885-91	8.4	6
16	Valsartan improves fibrinolytic balance in atherosclerotic rabbits. *Journal of Hypertension*, **2002**, 20, 303-10	1.9	25
15	Relevance of endothelium-derived hyperpolarizing factor in the effects of hypertension on rat coronary relaxations. *Journal of Hypertension*, **2001**, 19, 539-45	1.9	26
14	Effect of atorvastatin on endothelium-dependent constrictor factors in dyslipidemic rabbits. *General Pharmacology*, **2000**, 34, 263-72		15
13	The protective role of atorvastatin on function, structure and ultrastructure in the aorta of dyslipidemic rabbits. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2000**, 437, 545-54	5.1	13
12	AT(1) receptor antagonism reduces endothelial dysfunction and intimal thickening in atherosclerotic rabbits. *Hypertension*, **1999**, 34, 969-75	8.5	75
11	Effects of antihypertensive therapy on factors mediating endothelium-dependent relaxation in rats treated chronically with L-NAME. *Journal of Hypertension*, **1999**, 17, 221-7	1.9	25
10	In vivo tissue specific modulation of rat insulin receptor gene expression in an experimental model of mineralocorticoid excess. *Molecular and Cellular Biochemistry*, **1998**, 185, 177-82	4.2	16
9	Factors involved in the effects of losartan on endothelial dysfunction induced by aging in SHR. *Kidney International*, **1998**, 68, S30-5	9.9	16

8	Chronic treatment with losartan ameliorates vascular dysfunction induced by aging in spontaneously hypertensive rats. *Journal of Hypertension*, **1998**, 16, 665-72	1.9	23
7	Losartan reduces constrictor responses to endothelin-1 and the thromboxane A2 analogue in aortic rings from spontaneously hypertensive rats: role of nitric oxide. *Journal of Hypertension*, **1997**, 15, 1677-84	1.9	26
6	Endothelial dysfunction in spontaneously hypertensive rats: consequences of chronic treatment with losartan or captopril. *Journal of Hypertension*, **1997**, 15, 613-8	1.9	82
5	Nitric oxide, the kidney, and hypertension. *American Journal of Hypertension*, **1997**, 10, 129-40	2.3	53
4	Renal and vascular consequences of the chronic nitric oxide synthase inhibition. Effects of antihypertensive drugs. *American Journal of Hypertension*, **1996**, 9, 1077-83	2.3	32
3	Losartan reduces phenylephrine constrictor response in aortic rings from spontaneously hypertensive rats. Role of nitric oxide and angiotensin II type 2 receptors. *Hypertension*, **1996**, 28, 967-72	8.5	48
2	Nitric oxide and prostaglandins in the prolonged effects of losartan and ramipril in hypertension. *Hypertension*, **1995**, 26, 236-43	8.5	45
1	Molecular heterogeneity of circulating prolactin in chronic uremic men and renal transplant recipients. *Journal of Clinical Endocrinology and Metabolism*, **1986**, 62, 352-6	5.6	9